EPL Ltd Q1 FY27 Earnings Call — Analysis (NSE: EPL)
EPL delivered 25.3% revenue growth (20% underlying) and raised near-term growth guidance to high teens, driven by double-digit expansion across all regions and strong pricing pass-through.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q1FY27 Revenue Growth (Reported) 25.3% ( +25.3% YoY ) . New guidance — FY27 epl limited consolidated revenu… high teens . New story: Strategic diversification beyond tubes via Indo… .
Results
Revenue grew 25.3% YoY (underlying +20%), EBITDA rose 15.2% YoY with 18.8% reported margin (19.6% underlying), while PAT dipped 1.4% YoY due to a higher effective tax rate base.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue Growth (Reported) | 25.3% | +25.3% | yoy · Q1FY27 · YoY reported |
| Revenue Growth (Underlying) | 20.0% | +20.0% | yoy · Q1FY27 · Excluding RM pass-through |
| EBITDA Growth | 15.2% | +15.2% | yoy · Q1FY27 · YoY |
| EBITDA Margin (Reported) | 18.8% | none · Q1FY27 · Reported EBITDA margin | |
| EBITDA Margin (Underlying) | 19.6% | none · Q1FY27 · Underlying EBITDA margin | |
| PBT Growth | 10.0% | +10.0% | yoy · Q1FY27 · YoY |
| PAT Growth | -1.4% | -1.4% | yoy · Q1FY27 · YoY |
| ROCE | 18.5% | point_in_time · Q1FY27 · Jun-26 |
Guidance
Management raised near-term revenue growth guidance from low double digits to high teens while maintaining target underlying EBITDA margin of ~20% and double-digit full-year PAT growth.
What management committed to
- EPL expects to deliver high teens revenue growth over the next few quarters. — high teens, FY27
- EPL expects to maintain underlying EBITDA margin in the target range of 20%. — 20%, FY27
- EPL is on track to deliver double-digit PAT growth for the full year FY27. — double-digit, FY27
- EPL's full-year effective tax rate is expected to land between 20% and 22%. — 20% to 22%, FY27
- EPL targets doubling its Beauty & Cosmetics market share from 8% to 16% over the next few years. — 16%, in the next few years
- Europe EBITDA margins are expected to improve to the target range of mid-teens in the coming quarters. — mid-teens, FY27
Key themes
Pricing pass-through and broad-based category expansion
How the narrative shifted
- Cost inflation pass-through capability: Management asserts that blended customer pricing formulas and proactive engagement have successfully insulated margins from volatile commodity, freight, and FX cycles.
- Beauty & Cosmetics mix shift: Expansion in Beauty & Cosmetics (currently 54% with Personal Care) via front-end sales force division and specialized tooling is the primary vehicle for market share and margin expansion.
- Europe operational turnaround and investment: Despite temporary operational inefficiencies, management maintains high commitment to Europe by centralizing printing and service in Poland to capture large B&C demand.
- Strategic diversification beyond tubes via Indovida: The Indovida merger marks EPL's entry into rigid packaging and faster-growing emerging markets, paving the way for larger packaging TAM expansion.
Operational commentary
- Received Competition Commission of India (CCI) approval for the proposed merger with Indovida, progressing on planned timelines.
- Bifurcated front-end sales force into dedicated divisions for Beauty & Cosmetics versus Oral Care / large key accounts to drive specialized market penetration.
- Operations in Thailand are ramping up, securing recent wins with multinational customers in Beauty & Cosmetics.
- Set up a full-service Center of Excellence for Beauty & Cosmetics in India and expanding extruded tube and printing capabilities in Poland.
- Sustainable tube portfolio increased to 44% of overall product mix.
- Working capital increased by ~₹180 Cr during the quarter primarily due to higher raw material inventory pricing and strategic safety stocking.
Analyst Q&A
Q. Drivers of the ~₹180 Cr sequential net working capital increase and receivables status.
Increase was largely driven by higher inventory cost due to raw material inflation and building safety stocks to prevent supply disruption, alongside capex additions; receivables aging and days remain controlled despite higher absolute AR from price hikes.
Q. Reasons for Europe margin contraction and status of manufacturing footprint transitions.
Europe faced operational challenges which are identified and under resolution, alongside proactive investments in sales force and capacity in Poland/Germany; margins are expected to progressively recover to mid-teens.
Q. Breakdown of volume growth vs pricing/inflation pass-through.
Underlying revenue grew 20% excluding raw material pass-through, but exact volume growth metric was withheld because price variances across categories and regions make pure tube volumes less indicative.
Q. Specific synergy details and India market strategy for Indovida.
Management declined to share non-public strategic details or forward consolidated numbers because both entities remain separate pending final regulatory approvals.
Research and educational content only. Not investment advice.